Xuanzhu Pharma Co., Ltd.

Xuanzhu Biopharmaceutical Co., Ltd.

Yuzhen Feng

Jinyuan Wang

Zhenhua Wang

Chutian Shu

Lan Fang

The present disclosure relates to crystal form A of 5-((4-ethylpiperazin-1-yl)methyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-yl)pyrimidin-2-amine. The crystal form has a high purity, less residual solvent, high solubility and good stability; has good properties, fluidity and compressibility, and is convenient for production, detection, preparation of formulations, transportation and storage. The preparation method is easy to operate and is suitable for industrial production, and the crystal form can be used for treating and/or preventing diseases associated with CDK4/6 kinase-mediated cancers.

Crystal form targeting CDKkinase inhibitor

Provided are a maleate of a quinazoline derivative-like tyrosine kinase inhibitor represented by Formula (1), and a crystal form thereof and a preparation method therefor, a pharmaceutical composition comprising the maleate and the crystal form thereof, as well as use of the maleate and the crystal form thereof in the manufacture of a medicament for treating and/or preventing a hyperproliferative disease and a chronic obstructive pulmonary disease.

Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof

The invention relates to Crystal form I, Crystal form II and Crystal form III of N-(4-((3-chloro-4-fluorophenyl)amino)-7-((7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy)quinazolin-6-yl)acrylamide represented by the following Formula (I), and preparation methods thereof, wherein the Crystal form I has an X-ray powder diffraction pattern having characteristic peaks at the 2&#x3b8; positions of 6.7&#xb1;0.2&#xb0;, 7.9&#xb1;0.2&#xb0;, 8.6&#xb1;0.2&#xb0;, 12.0&#xb1;0.2&#xb0;, 13.9&#xb1;0.2&#xb0;, 15.9&#xb1;0.2&#xb0;, 17.3&#xb1;0.2&#xb0;, 18.3&#xb1;0.2&#xb0;, 18.7&#xb1;0.2&#xb0;, 21.0&#xb1;0.2&#xb0;, and 23.0&#xb1;0.2&#xb0;, as determined by using Cu-K&#x3b1; radiation; the Crystal form II has an X-ray powder diffraction pattern having characteristic peaks at the 2&#x3b8; positions of 6.9&#xb1;0.2&#xb0;, 8.5&#xb1;0.2&#xb0;, 14.8&#xb1;0.2&#xb0;, 15.6&#xb1;0.2&#xb0;, 16.7&#xb1;0.2&#xb0;, 17.1&#xb1;0.2&#xb0;, 17.9&#xb1;0.2&#xb0;, 18.7&#xb1;0.2&#xb0;, 19.1&#xb1;0.2&#xb0;, 21.5&#xb1;0.2&#xb0;, 23.5&#xb1;0.2&#xb0;, and 25.7&#xb1;0.2&#xb0;, as determined by using Cu-K&#x3b1; radiation; and the Crystal form III has an X-ray powder diffraction pattern having characteristic peaks at the 2&#x3b8; positions of 4.9&#xb1;0.2&#xb0;, 6.1&#xb1;0.2&#xb0;, 7.4&#xb1;0.2&#xb0;, 11.4&#xb1;0.2&#xb0;, 12.2&#xb1;0.2&#xb0;, 16.6&#xb1;0.2&#xb0;, and 18.4&#xb1;0.2&#xb0;, as determined by using Cu-K&#x3b1; radiation. 

Growing community of inventors

Jinan, China

Yuzhen Feng